Current issue #24, 2015
Procurement Moscow-style
PharmVestnik discovered a strange drug bidding announced by Moscow City Health Department
Moscow has failed to procure tuberculin for this year, although the city made certain attempts. Two biddings announced, respectively, in late 2014 and mid-2015, have been declared void because no players opted into these biddings. The conditions of biddings were designed in such a way that there was only one drug manufacturer meeting them, namely PAO Pharmstandard-Biolek. However, this is only an assumption because, notwithstanding the conditions of biddings allegedly formed to suit specifically Pharmstandard, this company has not bidden either.
[PharmVestnik # 24, 28/07/2015, p. 1, cont’d p. 5]
Fighting insubstantiality so far
Licenses may be revoked from pharmacies selling Rx drugs over-the-counter
A bill on strengthening responsibility for license violations was brought in to the State Duma. While looking for ways to influence pharmacies that unlawfully dispense pharmaceuticals most popular among drug addicts, lawmakers are trying to take a strict control over Rx drug sales at large. Most experts are sure that this idea will crush against the effects of real-life retailing, and suggest other solutions.
[PharmVestnik # 24, 28/07/2015, p. 2]
No methods ahead soon
Federal Antimonopoly Service (FAS) merged with Federal Tariff Service (FTS)
Premier Dmitry Medvedev has implemented his idea of integrating FTS within the framework of FAS. The integrated agency is headed by Igor Artemiev. Now the Pharma community gears up to live with the fact that the updated VED pricing methods are unlikely to appear before winter, and that FAS, with its inherent perfectionism, is trying to find out the rationale and procedures that the ex-FTS employees were guided by before.
[PharmVestnik # 24, 28/07/2015, p. 3]
Beyond any formal framework
The “Editorial Fireplace” rubric hosted Igor KRYLOV, Director for Government Relations and Strategic Development at AstraZeneca Russia&Eurasia. Mr. Krylov, ex-C...
Нет комментариев
Комментариев: 0